Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1189671 | 0.88 | HPGD (0.37) | F2REPHX2NR1H4CA5AMAPT | |
| SCHEMBL1188955 | 0.88 | F2R (0.42) | F2REPHX2NR1H4MAPTTACR1 | |
| SCHEMBL1188736 | 0.86 | F2R (0.42) | F2REPHX2NR1H4KAT6AMAPT | |
| SCHEMBL1188655 | 0.85 | CA1 (0.45) | F2RKAT6AMAPTALDH1A1LMNA | |
| SCHEMBL1188549 | 0.84 | EPHX2 (0.39) | EPHX2NR1H4CA5AMAPTALDH1A1 | |
| SCHEMBL1188098 | 0.84 | F2R (0.45) | F2REPHX2NR1H4KAT6AMAPT | |
| SCHEMBL1204935 | 0.84 | NR1H4 (0.38) | F2REPHX2NR1H4CA5AMAPT | |
| SCHEMBL1188489 | 0.84 | MAOB (0.47) | ALDH1A1MAOBTACR1LMNASMN1; SMN2 | |
| SCHEMBL1188648 | 0.81 | HDAC8 (0.36) | F2REPHX2NR1H4CA5AMAPT | |
| SCHEMBL14838198 | 0.81 | GABRA1 (0.44) | F2RTACR1ACHEGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240486-B1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINE | SANOFI SA (FR) | 2015-09-09 | — | — | EP | disclosed |
| EP-2240486-B1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINE | SANOFI SA (FR) | 2015-09-09 | — | — | EP | disclosed |
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-8853206-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| US-8853206-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| US-8853206-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-8198272-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI-AVENTIS (FR) | 2012-06-12 | — | — | US | disclosed |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| EP-2240487-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| EP-2240486-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009097971-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097971-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097970-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097970-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | F2R 1/4885EPHX2 2338/4885NR1H4 1837/4885 |
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | F2R 1/4885EPHX2 3475/4885NR1H4 1395/4885 |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | F2R 1/4885EPHX2 3329/4885NR1H4 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.